Advertisement
Advisory Board appointees include:
Susan B. Bayh, J.D. has been a director of Nastech since July 2005 as amember of the Compensation and chairman of the Nominating and CorporateGovernance Committees of the Board of Directors. Mrs. Bayh currently serves onthe boards of directors of Curis, Inc., a therapeutic drug developmentcompany, Dendreon Corporation, a therapeutic drug development company, DyaxCorp., a biopharmaceutical company, Emmis Communications, a diversified mediacompany, and Wellpoint, Inc., a Blue Cross / Blue Shield company. In addition,Mrs. Bayh is a member of the Audit and Compensation Committees of the board ofdirectors of Curis, Inc., and a member of the Compensation Committee of theboard of directors of Emmis Communications. Previously, Mrs. Bayh also servedon the boards of directors of Cubist Pharmaceuticals, Inc., a pharmaceuticalcompany, from 2000 to 2004, and Esperion Therapeutics, Inc., abiopharmaceutical company, from 2000 to 2003. From 1994 to 2004, she was aDistinguished Visiting Professor at the College of Business Administration atButler University in Indianapolis, Indiana. From 1994 to 2000, she was aCommissioner for the International Joint Commission of the Water Treaty Actbetween the United States and Canada. From 1989 to 1994, Mrs. Bayh served asan attorney in the Pharmaceutical Division of Eli Lilly and Company. Mrs. Bayhearned a Bachelor of Arts degree from the University of California at Berkeleyand received her J.D. degree from the University of Southern California LawCenter.
Advertisement
Alexander D. Cross, Ph.D. has been a director of Nastech since July 2005and is currently chairman of the Audit and a member of the Nominating andCorporate Governance Committees of the Board of Directors. Dr. Cross served onthe board of directors of Ligand Pharmaceuticals Inc. and was a member of itsAudit and Compensation Committees until March 2007. Dr. Cross also served asChairman of the Board and Chief Executive Officer of Cytopharm, Inc. untilAugust 2006. Dr. Cross has been a consultant in the fields of pharmaceuticalsand biotechnology since January 1986 and is presently a principal of NDAPartners. Previously, Dr. Cross served as President and Chief ExecutiveOfficer of Zoecon Corporation, a biotechnology company, from April 1983 toDecember 1985, and Executive Vice President and Chief Operating Officer from1979 to 1983. Dr. Cross also previously held several corporate managementpositions at Syntex Corporation from 1961 through 1979. Dr. Cross holds 109issued United States patents and is the author of 90 peer-reviewedpublications. Dr. Cross received his B.Sc., Ph.D. and D.Sc. degrees from theUniversity of Nottingham, England, and is a Fellow of the Royal Society ofChemistry.
Daniel L. Peters was most recently President and CEO of global MedicalDiagnostics at GE Healthcare. Prior to his role at GE Healthcare, Mr. Peterswas Chief Operating Officer at Amersham Health. Previously, he served as thePresident of Nycomed Amersham Imaging, where he was responsible for managingthe company's diagnostic pharmaceutical operations in North, South, andCentral America. Mr. Peters had been President of Nycomed Imaging Inc. in theAmericas from 1994 to 1997. Prior to that, he held roles of increasingresponsibility within the U.S. pharmaceuticals business of Sterling Winthropincluding marketing, strategic planning and general management, beingappointed President of the U.S. Pharmaceutical business in 1993. Mr. Peters isa former Trustee and founding member of the Health Care Institute of NewJe
